Introduction
Polioviruses are the causative agents of poliomyelitis and occur in three antigenically distinct serotypes, types 1, 2 and 3. The antigenic structure of poliovirus has been studied extensively, and several sites to which neutralizing antibodies bind have been identified by the isolation and characterization of antigenic variants (Minor et al., 1983 (Minor et al., , 1986 Diamond et al., 1985; Blondel et al., 1986; Page et al., 1988; Wiegers et al., 1989) . The atomic structures of the type 1 strain Mahoney (Hogle et al., 1985) and the Sabin type 3 strain Leon 12alb (Filman et al., 1989) have been determined, and the antigenic sites have been shown to form apparently distinct structural features on the virus surface. Full-length cDNA copies of the genome of both type 1 and 3 poliovirus strains can produce infectious virus when cells are transfected either with the cDNA or RNA produced from it. Recombinant DNA technology can therefore be used to exchange genomic regions encoding antigenic sites, and to observe the effect on the antigenic and other properties of the resulting virus.
Three or four main antigenic sites have been described for poliovirus, based on the isolation of mutants resistant to neutralization by monoclonal antibodies (MAbs). Site 1 consists chiefly of a continuous sequence of 12 amino acids in VP1, from residues 89 to 100 of type 3, together with additional sequences from VP1 in regions around amino acids 140, 165 and 255. The resulting complex forms the most prominent surface feature of the virus and is found at the pentameric apex of the virus. Several groups have modified site 1 by manipulating the principal component sequence (Burke et al., 1988; Murray et al., 1988a; Minor et al., 1990) . The resulting viruses express dual antigenicity to some extent, and foreign epitopes can be expressed (Colbere-Garapin et al., 1988; Evans et al., 1989; Jenkins et ai., 1990) ; the viruses may also have a different host range (Murray et al., 1988b; Martin et al., 1988) .
Site 2 is a complex site composed of a continuous sequence from VP2, in the region of amino acids 160 to 170, the C terminus of VP2 and a short continuous sequence from VP1 in the region of amino acid 220. Murdin & Wimmer (1989) reported modification of the VP2 component of this site in the type 1 strain Mahoney, to produce a type 2 sequence, and the resulting virus again expressed dual antigenicity to some extent. Site 3 consists of several elements from VP3, including residues in the region of amino acids 60 and 70, and a sequence from VP1 in the region of residues 280 to 290. Site 4, which bridges adjacent pentamers and is therefore expressed only on the assembled capsid, includes elements from VP3, in the region of amino acids 77 to 80, and VP2, in the region of amino acid 72. Modification of sites 3 and 4 to produce antigenic chimeras has not been described.
The work described here concerns the manipulation of sites 2, 3 and 4 of the Sabin type 1 strain to produce the 0001-0368 © 1991 SGM corresponding sequences of type 3. The s-carbon chains of the type 1 and 3 polioviruses, the structure of which has been determined are almost superimposable, except in regions corresponding to antigenic sites, in which many of the differences in amino acid sequence between the strains are found. Therefore there is reason to suppose that the antigenic sites could be transposed from one virus to the other, retaining their structural and antigenic properties. The construction of antigenic chimeras will help to establish the degree to which the sites are independent surface features, and, by transposing all the sites, it should be possible to determine the extent to which the antigenic structure of the virus is defined, to identify any virological function associated with antigenic features and to assess the feasibility of using this technology to produce novel vaccines against poliovirus or other agents (Evans et al., 1989; Murdin & Wimmer, 1989) .
Methods
Construction of chimeric viruses. Chimeras were constructed in a manner analogous to that previously described (Burke et al., 1988) using gapped, duplex oligonucieotide-directed mutagenesis to exchange regions encoding sites 2, 3 or 4 (Burke, 1989) . The constructs made are shown in Table 1 . Viruses were recovered by transfection of Hep2c cells (Burke et al., 1988) and the sequence of the insert was checked by sequencing the genomic RNA (Minor et al., 1986) . All viruses were neutralized by pooled human serum and infection was prevented by an MAb specific for the poliovirus receptor (Minor et al., 199O) .
Neutralization of viruses. Neutralization of viruses was measured by titre reduction in the presence of monospecific polyclonal antibodies or by serum endpoint dilution assays of MAbs, as described previously .
Tenfold dilutions of virus were incubated with a fixed dilution of monospecific polyclonal antisera, or medium alone, for 3 h at 35 °C. Hep2c cells were added and incubated for 5 to 7 days at 35 °C. The log10 TCIDso of virus was calculated in the presence and absence of antibody, and results were expressed as the log10 TCID5o titre reduction caused by an antibody.
Neutralization of virus by MAbs was measured by serum endpoint dilution assays using a 100 TCIDso virus challenge, as described previously .
Antigen blocking tests. Single radial immunodiffusion antigen blocking tests were performed as described (Ferguson et al., 1984) .
Agarose slabs containing polyclonal sera specific for type 1 or 3 poliovirus were prepared. The concentration of antibody was such that a zone of approximately 7 mm was produced after overnight diffusion of sucrose gradient-purified, [35S]methionine-labelled virus (109 p.f.u./ml). Antibody dilutions (20 ~tl; 10-fold steps) under test were added to the well and allowed to diffuse before addition of the labelled virus. Gels were dried and exposed to X-ray film. Reactions were assessed visually, the endpoint being defined as the lowest concentration of antibody that completely prevented diffusion.
Antipeptide sera. Rabbit sera were raised to synthetic peptides conjugated to keyhole limpet haemocyanin (KLH) with glutaraldehyde as described previously . A peptide representing Immunization of animals. Rabbits were immunized with 0-5 ml of sucrose gradient-purified virus containing about 108 p.f.u, of virus. Three doses, all in Freund's complete adjuvant, were given intramuscularly at 3 week intervals.
Results

Reactions of chimeras with monospecific antisera
The chimeras studied are shown in Table 1 and the sequence differences in Table 2 . Chimeras were incubated with dilutions of monospecific antisera which were known to neutralize all detectable infectivity of the parental Sabin strains of poliovirus, and residual virus was titrated. The results are summarized in Table 3 . As expected, no chimera was neutralized significantly by the type 2-specific antiserum. Virus S1/3.30 was a chimera in which the two major components of site 2 of the Sabin type 1 strain had been replaced by the equivalent regions of the Sabin type 3 strain (Table 1) , and was neutralized by the type 3 antiserum to a significant extent. Virus S1/3II. 1, which included only the VP2 component of the Sabin type 3 site 2 (Table 1) , may also have been neutralized partially by the antiserum. No other chimera was neutralized by the type 3-specific antiserum, implying that no other type 3 sites were presented in a recognizable form.
The type 1-specific serum was able to neutralize all detectable infectivity of the Sabin type 1 strain at a dilution of 1:200. However several chimeras were neutralized incompletely at this serum concentration, including S1/3II. 1, S1/3.14, S1/3.25 and S1/3.27. Low levels of infectivity also persisted in several other instances, although all the viruses were neutralized completely by higher concentrations of serum. These findings contrast with those obtained with site 1 chimeras, for which the type 1 antiserum was as effective against the chimeras as against the Sabin type 1 strain , and suggest that a significant proportion of the antibody response to type 1 is directed against sites 2, 3 and 4. This is consistent with the view that they constitute the major sites recognized by a neutralizing antibody response against type 1 poliovirus.
Reactions of chimeras with type 1-specific MAbs
Some of the chimeras were tested for their reaction in antigen blocking tests with 23 MAbs directed against known antigenic sites on type 1 poliovirus. This technique assesses antibody binding and requires the production of radiolabelled virus, which was only possible for the six viruses shown in Table 4 ; the other five grew too poorly for this purpose. The results in Table  4 support the view that the sites and their subcomponents are relatively independent structural features. All chimeras reacted to high titre with the antibodies directed against site 1, which had not been deliberately modified in these studies. Based on the isolation of antigenic mutants the most significant component of site 2 in type 1 is the VP1 component, which was substituted in chimera S1/3.29. This failed to react with all MAbs except 427, 428 and 432, which reacted to lower titres. By contrast, chimera S1/3II. 1, in which the major VP2 region is substituted, reacted with all the MAbs mapped to site 2 of type 1, including MAbs 237 and 271. This was unexpected as these two MAbs are affected by mutations in the VP2 component (Minor et al., 1986) substituted in S1/3II.1. S1/3.30, in which both components were modified to the sequence of type 3, failed to react with any site 2 MAb. All site 2 chimeras reacted to high titre with site 3-and site 4-specific MAbs, implying that site 2 is structurally relatively independent of sites 3 and 4. Site 3 consists of a component from VP1, which has been shown by the isolation of antigenic mutants to contribute to the site in type 3 , and components from VP3. The VP1 component had not been shown previously to contribute to the site in type 1, but S1/3.12, in which this region was modified, failed to react with MAb 960, one of the type 1-specific MAbs. The remaining four antibodies reacted with S 1/3.12, but failed to react with S1/3.25, in which the VP3 component had been replaced; S1/3.25 did react with MAb 960. Of the five MAbs against site 3, none reacted with S1/3.19, in which both components were substituted. The site 3 chimeras reacted to high titre with antibodies against all other sites, including site 4, implying that site 3 is also a relatively independent structural feature. All the chimeras, including those with poor growth properties, were assessed for their reaction in neutralization tests with a panel of six MAbs known to be of high titre and directed against sites on type 1 poliovirus defined by the isolation of mutants. The results are summarized in Table 5 . Three chimeras (S1/3.30, S1/3.12 and S1/3.13) gave anomalous results with site 1 MAbs, failing to be neutralized by either 955 or 956. S1/3.30 and S1/3.12 reacted as expected in antigen blocking tests (Table 3 ) and the results shown in Table 4 may indicate that the population is a mixture of a virus with the correct sequence in site 1 and a mutant. Viruses isolated from the neutralization tests with MAbs 955 and 956 had substitutions in site 1 which would explain their failure to be neutralized (data not shown). If the virus preparation is a mixture, it is not clear where the mutants arose. Variant sequences were not detectable in the starting virus preparation as cross bands on gels.
The other reactions were consistent with those shown in Table 4 . Thus, the effect of manipulating site 2 was confined to reactions with site 2-specific antibodies, and of manipulating site 3 to reactions with the site 3-specific antibody. An exception was the reaction of the only site 4 chimera, S1/3.15, which reacted normally with 234, a site 4-specific MAb selective for mutations in VP2 at residue 72, but not with 423, a site 3 MAb selective for mutations in VP3 at residue 60. As site 4 is composed of residues in VP3 between 77 and 80 close to those making up site 3 and, like site 3, is highly conformational then overlap between the two may not be surprising. This has not been shown previously by studies of mutants however, and may be due to conformational effects rather than contact residues in common between the two sites.
Reactions of chimeras with type 3-specific MAbs
Of the type 3-specific MAbs studied, six were directed against site 2 of mature infectious virus, or D antigen, 19 were directed against site 3 of mature infectious virus and two were known to be specific for the sequence making up site 3 as it is presented on heated virus, or C antigen Minor et al., 1986) . Two of the site 2-specific MAbs reacted with some of the chimeras (Table 6 ). MAbs 838 and 1280 reacted with all viruses that contain the VP2 component of site 2, including the Sabin type 3 strain, S1/3II. 1 and S1/3.30; MAbs 838 and 1280 did not react with S1/3.29, which contained only the VP1 component of site 2 of type 3. This is consistent with previous studies of antigenic mutants which suggest that the VP1 component of site 2 is less significant for the antigenicity of type 3 than for that of type I. The fact that only two of the MAbs reacted suggests that there are conformational elements in site 2 which were not adequately transposed from type 3 to type 1 in the chimeras. Also of interest was that binding of MAb 1280 in the antigen blocking test paralleled neutralization, whereas MAb 838 bound but did not neutralize the Sabin type 3 strain, but did neutralize the chimeras to which it bound. Of the 19 type 3 MAbs specific for site 3 of virus in the D antigenic configuration, none reacted with any chimera. Of the two MAbs reacting with a corresponding region on the denatured C antigenic form one, MAb 468, reacted with the Sabin type 3 strain, and chimeras S1/3.14, S1/3.19, S1/3.25 and S1/3.27 to similar titre in antigen blocking tests, but failed to react with S1/3. t2 or the Sabin type 1 strain (data not shown). Therefore, it reacted with all the chimeras tested which contained sequences from VP3 of type 3 from residues 55 to 62. The poor reactivity of the site 3-specific MAbs suggests that the highly conformational nature of site 3 on the type 3 virion is represented poorly in the chimeras. The reactivity of MAbs specific for the corresponding region in the C antigenic particle may suggest that the transposed sequence is more linear in heat-treated viruses, although this conclusion is speculative.
Reactions of chimeras with antipeptide sera
Peptides representing the VP2 component of site 2 of type 3 or the VP1 component of site 3 of type 3 were coupled to KLH and used to immunize rabbits. Rabbits were also immunized with a third peptide representing the VP2 component of site 2 of type 1. The reactions of the antisera with chimeras and the Sabin type 1 and 3 strains in antigen blocking tests are shown in Table 7 (a and b). For site 2, the anti-peptide sera specific for the type 3 VP2 component reacted with the Sabin type 3 strain, S1/3II. 1 and S1/3.30 to the same titres, but failed to recognize either the Sabin type 1 strain or S1/3.29. By contrast, the peptide sera specific for the type 1 sequence recognized the Sabin type 1 strain and S1/3.29; similar results were found in neutralizing antibody tests (data not shown). Antipeptide sera thus recognized virus presenting the homologous sequence whether it was found in the native virus or a chimera.
The antisera specific for the VP1 component of site 3 of type 3 recognized virus only in the C antigenic form, after heating ('fable 7b), but again it reacted to the same titre with the Sabin type 3 strain and chimera S1/3.19. This confirms the view based on MAb specificity ) that this sequence is exposed in different conformations on native and heated virus.
Induction of antibodies in rabbits by antigenic chimeras
Some of the chimeras were used to immunize rabbits, and the neutralizing antibody titres induced are presented in Table 8 . The level of antibody to the Sabin 1 strain induced in different rabbits was significant, although variable. Only one chimera, S1/3.30, induced detectable antibodies to the Sabin type 3 strain; this virus contains both components of site 2. The failure of the other chimeras to induce antibodies specific for type 3 is consistent with their generally poor reactivity with polyclonal antibodies and MAbs induced by type 3 strains (Table 3) , implying a generally inaccurate presentation of the site.
Discussion
The antigenic chimeras between type 1 and 3 polioviruses described here involved sites 2, 3 and 4 and, in contrast to previous findings concerning site 1 Burke et al., 1988; Murray et al., 1988a) , the viruses generally express the antigenic and immunogenic properties of the transposed type 3 sites poorly. The chief exceptions are some of the site 2 chimeras, for which the results described here are comparable to those of Murdin & Wimmer (1989) . These workers produced a type 1 chimera with site 2 of type 2, which reacts with polyclonal sera specific for type 2 and induces antibodies against type 2 (Murdin & Wimmer, 1989) ; the analogous type 1/type 3 chimeras described here express some type 3 antigenicity. By contrast, site 3 or 4 chimeras do not show any reactivity with type 3-monospecific sera in neutralization tests, neither do they induce any antibody able to neutralize type 3. The chimeras react poorly with the type 3-specific MAb panels, reflecting generally poor expression of the sites. Two antibodies from a panel of six specific for site 2 do react, of which one is able to neutralize the chimera but not the parental virus. This is potentially of interest in studying mechanisms of neutralization. Type 3 site 3 MAbs do not react with the chimeras in their infectious, D antigenic form, although one of two site 3, C-specific MAbs does react with a chimera expressing the VP3 component of the site. This suggests that this component of site 3 may be highly constrained and conformational in D antigen, but more extended and continuous in the C form. The results with sera raised against peptides confirm the view ) that if such antibodies can react with the parental virus they will also react with the chimera: Thus, it is clearly possible to express antigenic sites composed of a continuous sequence of amino acids, such as site 1 , the VP2 component of site 2 and the VPI component of site 3 expressed on C antigen, in chimeras. It is not clear whether strongly conformational sites, such as the VP3 component of site 3 in the native virus, can be so expressed.
Reactions with monospecific sera and MAbs against type 1 support the view that sites 2, 3 and 4 are the main targets for neutralizing antibody in the sera examined, and that the sites and their components act largely independently of each other, although there is evidence of some link between the VP3 components of sites 4and 3. Despite this, and the great similarity in the ~-carbon chain of types 1 and 3, it is clear that the transfer of functional antigenic sites from type 3 to type 1 is not straightforward. There is also an effect on virus growth (data not shown) which may be compensated in part by transferring more components of a site as a unit. Thus, S1/3.19 grows better and is a more stable virus than S1/3.14, from which it was obtained. It is possible that relatively slight changes in the amount of type 3 sequence transferred will dramatically improve the quality of the chimeric virus and its expression of type 3 antigenic properties.
